HRP20100713T1 - Derivati azola i tiazola i njihova upotreba - Google Patents

Derivati azola i tiazola i njihova upotreba Download PDF

Info

Publication number
HRP20100713T1
HRP20100713T1 HR20100713T HRP20100713T HRP20100713T1 HR P20100713 T1 HRP20100713 T1 HR P20100713T1 HR 20100713 T HR20100713 T HR 20100713T HR P20100713 T HRP20100713 T HR P20100713T HR P20100713 T1 HRP20100713 T1 HR P20100713T1
Authority
HR
Croatia
Prior art keywords
phenyl
alkyl
compound according
methyl
cyclohexyl
Prior art date
Application number
HR20100713T
Other languages
English (en)
Inventor
Charles Ray Nicholas
James Bull Richard
Finch Harry
Van Den Heuvel Marco
Antonio Bravo Jose
Original Assignee
Pulmagen Therapeutics (Synergy) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics (Synergy) Limited filed Critical Pulmagen Therapeutics (Synergy) Limited
Publication of HRP20100713T1 publication Critical patent/HRP20100713T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Spoj formule (I): naznacen time da (i) R1 je C1-C6-alkil ili vodik; i R2 je vodik ili skupina -R7, -Z-Y-R7, -Z-NR9R10; -Z-CO-NR9R10, -Z-NR9-C(O)O-R7, ili -Z-C(O)-R7; i R3 je usamljeni par, ili C1-C6-alkil; ili (ii) R1 i R3 zajedno sa dusikom na koji su spojeni tvore heterocikloalkilni prsten, i R2 je usamljeni par ili skupina -R7, -Z-Y-R7, -Z-NR9A10, -Z-CO-NR9R10, -Z-NR9-C(O)O-R7; ili; -Z-C(O)-R7; ili (iii) R1 i R2 zajedno sa dusikom na koji su spojeni tvore heterocikloalkilni prsten, navedeni prsten je supstituiran sa skupinom -Y-R7, -Z-Y-R7, -Z-NR9R10; -Z-CO-NR9R10; -Z-NR9-C(O)O-R7; ili; -Z-C(O)-R7; i R3 je usamljeni par, ili C1-C5-alkil; kombinacije R4 i R5 su one pri cemu (i) svaki od R4 i R5 je monociklicki heteroaril sa 5 ili 6 atoma u prstenu; (ii) svaki od R4 i R5 je fenil; (iii) jedan od R4 i R5 je fenil, a drugi je cikloalkil; i (iv) jedan od R4 i R5 je monociklicki heteroaril sa 5 ili 6 atoma u prstenu, a drugi je cikloalkil; R6 je -OH, C1-C6-alkil, C1-C6-alkoksi, hidroksi-C1-C6-alkil, nitril, skupina CONR82 ili atom vodika; A je kisik ili atom sumpora; X je alkilen, alkenilen ili alkinilenska skupina; R7 je C1-C6-alkil, aril, aril-fuzionirani-cikloalkil, aril-fuzionirani-heterocikloalkil, heteroaril, aril(C1-C6-alkil)-, heteroaril(C1-C6-alkil)-, cikloalkil ili heterocikloalkilna skupina; R8 je C1-C6-alkil ili atom vodika; Z je C1-C16-alkilen, C2-C16-alkenilen ili C2-C16-alkinilenska skupina; Y je veza ili atom kisika; R9 i R10 su nezavisno atom vodika, C1-C6-alkil, aril, aril-fuzionirani-heterocikloalkil, aril-fuzionirani-cikloalkil, heteroaril, aril(C1-C6-alkil ili heteroaril(C1-C6-alkil)- skupina; ili R9 i R10 zajedno sa atomom dusika na koji su spojeni tvore heterociklicki prsten od 4-8 atoma, koji opcijski sadrzi daljnji dusik ili atom kisika; pri cemu, bilo koji aril, heteroaril, cikloalkil, aril-fuzionirani-cikloalkil, heterocikloalkil, i aril-fuzionirani-heterocikloalkil skupina moze biti supstituirana sa jednom ili vise supstitucijskih skupina odabranih od acil, alkoksi, alkoksikarbonil, alkilamino, alkilsulfinil, alkilsulfonil, alkiltio, -NH2, aminoacil, aminoalkil, alkilaminoalkil, arilalkil, cijano, dialkilamino, halo, haloalkoksi, haloalkil, alkil, -OH, - CHO, -COOH, -NO2, aril (opcijski supstituiran sa alkoksi, haloalkoksi, halogen, alkil ili haloalkil), heteroaril (opcijski supstituiran sa alkoksi, haloalkoksi, halogen, alkil ili haloalkil), heterocikloalkil, aminoacil, aminosulfonil, acilamino, sulfonilamino, heteroarilalkil, ciklicki amin, ariloksi, heteroariloksi, arilalkiloksi i heteroarilalkiloksi; ili njegova farmaceutski prihvatljiva sol, solvat ili N-oksid. Patent sadrzi jos 39 patentnih zahtjeva.

Claims (40)

1. Spoj formule (I): [image] naznačen time da (i) R1 je C1-C6-alkil ili vodik; i R2 je vodik ili skupina -R7, -Z-Y-R7, -Z-NR9R10; -Z-CO-NR9R10, -Z-NR9-C(O)O-R7, ili -Z-C(O)-R7; i R3 je usamljeni par, ili C1-C6-alkil; ili (ii) R1 i R3 zajedno sa dušikom na koji su spojeni tvore heterocikloalkilni prsten, i R2 je usamljeni par ili skupina -R7, -Z-Y-R7, -Z-NR9A10, -Z-CO-NR9R10, -Z-NR9-C(O)O-R7; ili; -Z-C(O)-R7; ili (iii) R1 i R2 zajedno sa dušikom na koji su spojeni tvore heterocikloalkilni prsten, navedeni prsten je supstituiran sa skupinom -Y-R7, -Z-Y-R7, -Z-NR9R10; -Z-CO-NR9R10; -Z-NR9-C(O)O-R7; ili; -Z-C(O)-R7; i R3 je usamljeni par, ili C1-C5-alkil; kombinacije R4 i R5 su one pri čemu (i) svaki od R4 i R5 je monociklički heteroaril sa 5 ili 6 atoma u prstenu; (ii) svaki od R4 i R5 je fenil; (iii) jedan od R4 i R5 je fenil, a drugi je cikloalkil; i (iv) jedan od R4 i R5 je monociklički heteroaril sa 5 ili 6 atoma u prstenu, a drugi je cikloalkil; R6 je -OH, C1-C6-alkil, C1-C6-alkoksi, hidroksi-C1-C6-alkil, nitril, skupina CONR82 ili atom vodika; A je kisik ili atom sumpora; X je alkilen, alkenilen ili alkinilenska skupina; R7 je C1-C6-alkil, aril, aril-fuzionirani-cikloalkil, aril-fuzionirani-heterocikloalkil, heteroaril, aril(C1-C6-alkil)-, heteroaril(C1-C6-alkil)-, cikloalkil ili heterocikloalkilna skupina; R8 je C1-C6-alkil ili atom vodika; Z je C1-C16-alkilen, C2-C16-alkenilen ili C2-C16-alkinilenska skupina; Y je veza ili atom kisika; R9 i R10 su nezavisno atom vodika, C1-C6-alkil, aril, aril-fuzionirani-heterocikloalkil, aril-fuzionirani-cikloalkil, heteroaril, aril(C1-C6-alkil ili heteroaril(C1-C6-alkil)- skupina; ili R9 i R10 zajedno sa atomom dušika na koji su spojeni tvore heterociklički prsten od 4-8 atoma, koji opcijski sadrži daljnji dušik ili atom kisika; pri čemu, bilo koji aril, heteroaril, cikloalkil, aril-fuzionirani-cikloalkil, heterocikloalkil, i aril-fuzionirani-heterocikloalkil skupina može biti supstituirana sa jednom ili više supstitucijskih skupina odabranih od acil, alkoksi, alkoksikarbonil, alkilamino, alkilsulfinil, alkilsulfonil, alkiltio, -NH2, aminoacil, aminoalkil, alkilaminoalkil, arilalkil, cijano, dialkilamino, halo, haloalkoksi, haloalkil, alkil, -OH, - CHO, -COOH, -NO2, aril (opcijski supstituiran sa alkoksi, haloalkoksi, halogen, alkil ili haloalkil), heteroaril (opcijski supstituiran sa alkoksi, haloalkoksi, halogen, alkil ili haloalkil), heterocikloalkil, aminoacil, aminosulfonil, acilamino, sulfonilamino, heteroarilalkil, ciklički amin, ariloksi, heteroariloksi, arilalkiloksi i heteroarilalkiloksi; ili njegova farmaceutski prihvatljiva sol, solvat ili N-oksid.
2. Spoj prema zahtjevu 1 naznačen time da: R1 je C1-C6-alkil ili atom vodika; R2 je C1-C6-alkil, atom vodika ili skupina -Z-Y-R7 i R3 je usamljeni par ili C1-C6-alkil, ili R1 i R2 zajedno sa dušikom na koji su spojeni predstavljaju heterocikloalkilni prsten, ili R1 i R3 zajedno sa dušikom na koji su spojeni predstavljaju heterocikloalkilni prsten; kombinacije R4 i R5 su one pri čemu (i) svaki od R4 i R5 je monociklički heteroaril sa 5 ili 6 atoma u prstenu; (ii) svaki od R4 i R5 je fenil; (iii) jedan od R4 i R5 je fenil i drugi je cikloalkil; i (iv) jedan od R4 i R5 je monociklički heteroaril sa 5 ili 6 atoma u prstenu, a drugi je cikloalkil; R6 je -OH, C1-C6-alkil, hidroksi-C1-C6-alkil ili atom vodika; A je kisik ili atom sumpora; X je alkilen, alkenilen ili alkinilenska skupina; Z je alkilen, alkenilen ili alkinilenska skupina; Y je veza ili atom kisika; R7 je aril, heteroaril, heterocikloalkil, koji aril, heteroaril ili heterocikloalkil može biti supstituiran sa jednom ili više supstitucijskih skupina kako je definirano u zahtjevu 1.
3. Spoj prema zahtjevu 1 ili zahtjevu 2 naznačen time da R1 je metil ili etil, ili atom vodika; R2 je vodik, C1-C6-alkil, ili skupina -R7, -Z-Y-R7, -Z-NR9R10, -Z-CO-NR9R10, -Z-NR9-C(O)O-R7ili -Z-C(Q)-R7; i R3 je usamljeni par, ili C1-C6-alkil u kojem slučaju atom dušika na koji je spojen je kvaterni dušik i nosi pozitivni naboj.
4. Spoj prema zahtjevu 3 naznačen time da R3 je metil, tako da atom dušika na koji je spojen je kvaterni dušik i nosi pozitivni naboj.
5. Spoj prema zahtjevu 1 ili zahtjevu 2 naznačen time da R1 i R3 zajedno sa dušikom na koji su spojeni tvore monociklički heterocikloalkilni prsten od 3 do 7 atoma u prstenu, u kojem hetero-atomi su dušik; i R2 je usamljeni par ili C1-C6-alkil, ili skupina -R7 -Z-Y-R7, -Z-NR9R10. -Z-NR9-C(O)O-R7 ili -Z-C(O)-R7.
6. Spoj prema zahtjevu 5 naznačen time da R1 i R3 zajedno sa dušikom na koji su spojeni tvore azetidinilski, piperidinilski, piperazinilski, N-metilpiperazinilski, ili pirolidinilski prsten.
7. Spoj prema zahtjevu 5 ili zahtjevu 6 naznačen time da atom dušika na koji R1 i R3, ili R1 i R2, su spojeni je kvaterni dušik i nosi pozitivni naboj.
8. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time, da u bilo kojoj skupini - R7, -Y-R7, -Z-Y-R7, -Z-NR9R10, -Z-CO-NR9R10, -Z-NR9-C(O)O-A7 ili ; -Z-C(O)-R7: Z je -(CH2)1-8-, opcijski supstituiran na do tri ugljika sa metilom, Y je veza ili -O-; R7 je metil, etil, n- ili izopropil, n-, sek- ili tercbutil; ili fenil, 3,4-metilendioksifenil, 3,4-etilendioksifenil, dihidrobenzofuranil, naftil; ili piridil, pirolil, pirimidinil, oksazolil, izoksazolil, benzizoksazolil, benzoksazolil, tiazolil, benztiazolil, kvinolil, tienil, benztienil, furil, benzfuril, imidazolil, benzimidazolil, izotiazolil, benzizotiazolil, pirazolil, izotiazolil, triazolil, benztriazolil, tiadiazolil, oksadiazolil, piridazinil, piridazinil, triazinil, indolil ili indazolil; ili arilalkil pri čemu arilni dio je fenil, 3,4-metilendioksifenil, 3,4-etilendioksifenil, dihidrobenzofuranil, ili naftil, i -(C1-C6-alkil)- dio je -CH2- ili -CH2CH2-; ili heteroarilalkil pri čemu heteroarilni dio je piridil, pirolil, pirimidinil, oksazolil, izoksazolil, benzizoksazolil, benzoksazolil, tiazolil, benztiazolil, kvinolil, tienil, benztienil, furil, benzfuril, imidazolil, benzimidazolil, izotiazolil, benzizotiazolil, pirazolil, izotiazolil, triazolil, benztriazolil, tiadiazolil, oksadiazolil, piridazinil, piridazinil, triazinil, indolil ili indazolil, i -(C1-C6-alkil)- dio je -CH2- ili -CH2CH2-; ili indanil ili 1,2,3,4-tetrahidronaftalenil; ili ciklopropil, ciklobutil, ciklopentil ili cikloheksil; i R9 i R10 su nezavisno odabrani od vodika; C1-C6-alkila; ili bilo koji od njih opcijski supstituirani aril, aril-fuzionirani-heterocikloalkil heteroaril ili aril(C1-C8-alkil)- skupine posebno definirane za R7 u ovom zahtjevu; ili R9 i R10 zajedno sa atomom dušika na koji su spojeni tvore heterociklički prsten sa 4-8 atoma u prstenu koji opcijski sadrži daljnji dušik ili atom kisika; i kada R1 je heteroaril, cikloalkil, aril-fuzionirani-cikloalkil, heterocikloalkil, ili aril-fuzionirani-heterocikloalkil skupina, može biti supstituirana sa jednom ili više supstitucijskih skupina kako je definirano u zahtjevu 1.
9. Spoj prema zahtjevu 1 naznačen time, da u skupini -NR1R2R3, R1 je metil ili etil, R2 je -Z-NR9R10 ili -Z-Y-R7, Y je veza ili -O-, i -Z- je ravni ili razgranati radikal alkilena koji veže dušik i -NR9R10 ili -YR7 sa lancem sa do 16 atoma ugljika, i R3 je metil.
10. Spoj prema zahtjevu 9 naznačen time da R7 je fenil, benzil, dihidrobenzofuril ili feniletil, koji fenil, benzil, dihidrobenzofuril ili feniletil mogu biti supstituirani sa jednim ili više supstitucijskih skupina kako je definirano u zahtjevu 1.
11. Spoj prema zahtjevu 9 ili zahtjevu 10 naznačen time da R9 i R10 su kako je definirano u zahtjevu 8.
12. Spoj prema zahtjevu 1 naznačen time, da u skupini -NR1R2R3, R2 je -Z-NR9R10 ili -Z-Y-R7, Y je veza ili -O-, i -Z- je ravni ili razgranati radikal alkilena koji veže dušik i -NR9R10 ili -YR7 sa lancem sa do 16 atoma ugljika, i R1 i R3 zajedno sa dušikom na koji su spojeni tvore heterociklički prsten sa 4-8 atoma u prstenu, opcijski sadrže daljnji dušik ili atom kisika.
13. Spoj prema zahtjevu 12 naznačen time da R1 i R3 zajedno sa dušikom na koji su spojeni tvore azetidinilski, piperidinilski, piperazinilski, N-metilpiperazinilski, pirolidinilski, morfolinilski, ili tiomorfolinilski prsten.
14. Spoj prema zahtjevu 12 ili zahtjevu 13 naznačen time da R7 je ciklička lipofilna skupina kao što je fenilna, benzilna, dihidrobenzofurilna ili feniletilna, koja fenilna, benzilna, dihidrobenzofurilna ili feniletilna skupina može biti supstituirana sa jednom ili više supstitucijskih skupina kako je definirano u zahtjevu 1.
15. Spoj prema bilo kojem od zahtjeva 12 do 14 naznačen time da R9 i R10 su kako je definirano u zahtjevu 8.
16. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da (i) svaki od R4 i R5 je tienil; ili (ii) svaki od R4 i R5 je fenil; ili (iii) jedan od R4 i R5 je fenil, a drugi je ciklopentil ili cikloheksil; ili (iv) jedan od R4 i R5 je tienil, a drugi je ciklopentil ili cikloheksil.
17. Spoj prema zahtjevu 16 naznačen time da R6 je -OH.
18. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da R8 je vodik.
19. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da X je -CH2- ili -CH2CH2-.
20. Spoj prema zahtjevu 1 koji je formule (IA) [image] naznačen time da A je -O- ili -S-; m je 1 ili 2; prsten A je opcijski supstituiran fenilni prsten, ili monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu, ili fenil-fuzionirani-heterocikloalkilni sustav prstena pri čemu je heterocikloalkilni prsten monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu; R4 je fenil, tienil, ciklopentil ili cikloheksil; R5 je fenil; tienil, ciklopentil ili cikloheksil; s je 1, 2, 3, 4, 5, 6 ili 7 i t je 0, 1, 2, 3, 4, 5, 6 ili 7 pod uvjetom da s+t nije veće od 16; Y je veza ili -O-, i X- je farmaceutski prihvatljiv anion.
21. Spoj prema zahtjevu 1 koji je formule (IB) [image] naznačen time da A je -O- ili -S-; m je 1 ili 2; prsten B je pirolidinski ili piperidinski prsten; prsten A je opcijski supstituiran fenilni prsten, ili monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu, ili fenil-fuzionirani-heterocikloalkilni sustav prstena pri čemu je heterocikloalkilni prsten monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu; R4 je fenil, tienil, ciklopentil ili cikloheksil; R5 je fenil; tienil, ciklopentil ili cikloheksil; s je 1, 2, 3, 4, 5, 6 ili 7 i t je 0, 1, 2, 3, 4, 5, 6 ili 7 pod uvjetom da s+t nije veće od 16; Y je veza ili -O-, i X- je farmaceutski prihvatljiv anion.
22. Spoj prema zahtjevu 20 ili zahtjevu 21 naznačen time da prsten A je (i) opcijski supstituiran fenil, pri čemu su opcijski supstituenti odabrani od C1-C3alkoksi, halo, C1-C3-alkil, amino C1-C3-acil, i amino C1-C3-alkil, ili (ii) fenil-fuzionirani-heterocikloalkilni sustav prstena pri čemu je heterocikloalkilni prsten monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu.
23. Spoj prema bilo kojem od zahtjeva 20 do 22 naznačen time da t je 0, 1, 2, 3, 4, 5 ili 6 i s je 1, 2, 3, 4, 5, 6 ili 7 i s+t je 1, 2, 3, 4, 5, 6, ili 7.
24. Spoj prema zahtjevu 20 ili zahtjevu 21 naznačen time da t je 0, s je 3, i Y je -O-.
25. Spoj prema zahtjevu 20 ili zahtjevu 21 naznačen time da Y je veza i s+t je 2, 3 ili 4.
26. Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja se sastoji od: [2-(Hidroksi-difenil-metil)-oksazol-5-ilmetil]-dimetil-(3-fenoksi-propil)-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(3-fenoksipropil)-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-fenetilamonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(4-metil-pent-3-enil)-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-[2-(2,3-dihidrobenzofuran-5-il)-etil]-dimetil-amonijevih soli [2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(6-metil-piridin-2-ilmetil)-amonijevih soli [2-(Ciklopentil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(3-fenoksi-propil)-amonijevih soli [2-(Ciklopentil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(3-fenoksi-propil)-amonijevih soli 1-[2-(Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-1-(3-fenoksi-propil)-pirolidinskih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(4-fenoksi-butil)-amonijevih soli (2-Benziloksi-etil)-[2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(4-fenil-butil)-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-[3-(4-fluoro-fenoksi)-propil]-dimetil-amonijevih soli [2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(3-fenilpropil)-amonijevih soli [2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(2-fenoksietil)-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(3-p-toliloksipropil)-amonijevih soli [3-(4-Kloro-fenoksi)-propil]-[2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-amonijevih soli [2-((R)-Cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-[3-(3,4-dikloro-fenoksi)-propil]-dimetil-amonijevih soli [2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-(8-metilamino-octyl)-amonijevih soli [2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-[2-(4-metilaminometil-fenil)-etil]-amonijevih soli {2-[2-(Cikloheksil-hidroksi-fenil-metil)-oksazol-5-il]-etil}-dimetil-(3-fenoksipropil)-amonijevih soli {2-[2-(Cikloheksil-hidroksi-fenil-metil)-oksazol-5-il]-etil}-dimetil-(3-fenoksi-propil)-amonijevih soli, i (2-[2-(Hidroksi-difenil-metil)-oksazol-5-yi]-etil)-dimetil-(3-fenoksi-propil)-amonijevih soli [2-(Hidroksidifenilmetil)tiazol-5-ilmetil]dimetil-(3-fenoksipropil)amonijevih soli (3-Benziloksipropil)-[2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-amonijevih soli [2-(4-Kloro-benziloksi)-etil]-[2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-amonijevih soli.
27. Spoj prema zahtjevu 1, naznačen time da je [2-((R)-Cikloheksil-hidroksi-fenilmetil)-oksazol-5-ilmetil]-dimetil-(3-fenoksi-propil)-amonijeva sol.
28. Spoj prema zahtjevu 1, naznačen time da je [2-((R)-Cikloheksil-hidroksi-fenilmetil)-oksazol-5-ilmetil]-[3-(3,4-dikloro-fenoksi)-propil]-dimetil-amonijeva sol.
29. Spoj prema zahtjevu 1, naznačen time da je [2-(4-Kloro-benziloksi)-etil]-[2-((R)-cikloheksil-hidroksi-fenil-metil)-oksazol-5-ilmetil]-dimetil-amonijeva sol.
30. Spoj prema zahtjevu 1, naznačen time da je [2-((R)-Cikloheksil-hidroksi-fenilmetil)-oksazol-5-ilmetil]-dimetil-(2-fenetiloksi-etil)-amonijeva sol.
31. Spoj prema zahtjevu 1, naznačen time da je [2-((R)-Cikloheksil-hidroksi-fenilmetil)-oksazol-5-ilmetil]-[2-(3,4-dikloro-benziloksi)-etil]-dimetil-amonijeva sol.
32. Spoj prema bilo kojem od prethodnih zahtjeva, koji je izmijenjen zamjenom R2 skupine sa -L-B skupinom naznačen time L je vezujući radikal i B je dio koji ima β2 aktivnost adrenoreceptorskog agonista.
33. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je za upotrebu kod liječenja.
34. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 32 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
35. Farmaceutski pripravak prema zahtjevu 34 naznačen time da je u obliku pogodnom za inhalaciju.
36. Uporaba spoja prema bilo kojem od zahtjeva 1 do 32 naznačena time da je za proizvodnju lijeka za korištenje kod tretmana prevencije bolesti ili stanja kod kojih je bolest ili stanje poremećaj dišnog sustava.
37. Uporaba prema zahtjevu 36, naznačena time da bolest ili stanje je kronična opstruktivna bolest pluća, kronični bronhitis, astme, kronična respiratorna opstrukcija, bronhijalna hiperaktivnost, plućna fibroza, plućni emfizem ili alergijski rinitis.
38. Uporaba spoja prema bilo kojem od zahtjeva 1 do 32 naznačena time da je za proizvodnju lijeka za korištenje kod tretmana prevencije bolesti ili stanja kod kojih je bolest ili stanje upalna bolest crijeva, spazmični kolitis, ulkus gastroduodenuma, probavni grčevi ili hiperanakinezija, divertikulitis, bol uz grčeve gastrointestinalne glatke muskulature, poremećaj urinarnog trakta, uz poremećaj mokrenja uključujući neurogenu polakiuriju, neurogeni poremećaj mjehura, noćno mokrenje, psihosomatski poremećaj mjehura, inkontinencija povezana s grčevima mjehura ili kronični cistitis, učestalo mokrenje ili polakiurija, bolest kretanja i kardiovaskularne poremećaje, kao što je vagalno inducirana sinusna bradikardija.
39. Kombinacija koja sadrži spoj prema bilo kojem od zahtjeva 1 do 31 i jedno ili više anti-upalnih sredstava, bronhodilatatorskih sredstava, antihistaminskih sredstava, sredstava za smanjivanje kongestije ili sredstava protiv kašlja, naznačena time da navedeni spoj prema bilo kojem od zahtjeva 1 do 31 i navedena kombinacija sredstava mogu postojati u istom ili različitom farmaceutskom pripravku i mogu se primjenjivati odvojeno ili istovremeno.
40. Kombinacija prema zahtjevu 39 naznačena time da navedena kombinacija sadrži prema bilo kojem od zahtjeva 1 do 31 i β2-adrenoceptorski agonist.
HR20100713T 2005-08-08 2010-12-21 Derivati azola i tiazola i njihova upotreba HRP20100713T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516313.4A GB0516313D0 (en) 2005-08-08 2005-08-08 Azole derivatives and their uses
PCT/GB2006/002956 WO2007017669A1 (en) 2005-08-08 2006-08-08 Azole and thiazole derivatives and their use

Publications (1)

Publication Number Publication Date
HRP20100713T1 true HRP20100713T1 (hr) 2011-01-31

Family

ID=34984297

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100713T HRP20100713T1 (hr) 2005-08-08 2010-12-21 Derivati azola i tiazola i njihova upotreba

Country Status (28)

Country Link
US (2) US20100113540A1 (hr)
EP (2) EP2280006A1 (hr)
JP (1) JP5047175B2 (hr)
KR (1) KR20080046179A (hr)
CN (1) CN101282949B (hr)
AT (1) ATE485282T1 (hr)
AU (1) AU2006277768B2 (hr)
BR (1) BRPI0614291A2 (hr)
CA (1) CA2617964A1 (hr)
CY (1) CY1111720T1 (hr)
DE (1) DE602006017715D1 (hr)
DK (1) DK1924570T3 (hr)
EC (1) ECSP088253A (hr)
ES (1) ES2352755T3 (hr)
GB (1) GB0516313D0 (hr)
HK (1) HK1117147A1 (hr)
HR (1) HRP20100713T1 (hr)
IL (1) IL189267A (hr)
NO (1) NO20081214L (hr)
NZ (1) NZ566069A (hr)
PL (1) PL1924570T3 (hr)
PT (1) PT1924570E (hr)
RS (1) RS51547B (hr)
RU (1) RU2436779C2 (hr)
SI (1) SI1924570T1 (hr)
UA (1) UA95255C2 (hr)
WO (1) WO2007017669A1 (hr)
ZA (1) ZA200801603B (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501533A (ja) * 2006-08-21 2010-01-21 アージェンタ ディスカバリー リミテッド Ｍ３レセプター調節物質として有用な窒素含有複素環化合物
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702414D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702416D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
EP2118078A2 (en) * 2007-02-07 2009-11-18 Argenta Discovery Ltd New salt
WO2008096129A1 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702382D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
UY30916A1 (es) * 2007-02-15 2008-09-30 Argenta Discovery Ltd Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
US20110136843A1 (en) * 2007-02-23 2011-06-09 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2008133900A1 (en) 2007-04-24 2008-11-06 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
WO2008149110A1 (en) * 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
MX2010002576A (es) 2007-09-07 2010-04-01 Theravance Inc Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos.
WO2009079392A1 (en) 2007-12-14 2009-06-25 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
WO2009098455A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
BRPI0822693A2 (pt) 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
WO2010015792A1 (en) * 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US10689344B2 (en) 2013-11-07 2020-06-23 University Of Kansas Biphenylamide derivative Hsp90 inhibitors
PL3196200T3 (pl) * 2014-08-26 2019-09-30 Astellas Pharma Inc. Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AU2021236130A1 (en) * 2020-03-11 2022-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112023021140A2 (pt) * 2021-04-16 2023-12-12 Ads Therapeutics Llc Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307141B1 (en) * 1987-09-10 1993-01-13 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
IL88846A0 (en) 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
GB2214180A (en) 1988-01-12 1989-08-31 Shell Int Research Pytotoxic pyrrole-3,4-dicarboxylate derivatives
US5185354A (en) * 1990-06-18 1993-02-09 Mitsubishi Kasei Corporation Pyrazolecarboxamide, insecticidal and miticidal composition, and fungicidal composition for use in agriculture and horticulture
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
JPH0525045A (ja) 1991-07-18 1993-02-02 Tanabe Seiyaku Co Ltd 経皮吸収製剤
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
GB9603755D0 (en) 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6384035B1 (en) * 1997-10-09 2002-05-07 Ortho-Mcneil Pharmaceutical, Inc. Heterocycles useful in the treatment of benign prostatic hyperplasia
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
WO1999038864A1 (en) * 1998-02-03 1999-08-05 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
IL152140A0 (en) 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
IL154175A0 (en) 2000-08-05 2003-07-31 Glaxo Group Ltd 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
ATE399174T1 (de) 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
NZ536337A (en) 2002-04-12 2007-05-31 Boehringer Ingelheim Pharma Medicaments containing betamimetic drugs and a novel anticholinesterase drug
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
DE60315862T2 (de) 2002-08-27 2008-05-15 Bayer Healthcare Ag Dihydropyridinonderivate als hne-inhibitoren
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
MXPA05002644A (es) 2002-09-10 2005-09-20 Bayer Healthcare Ag Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
CA2498052C (en) 2002-09-10 2011-05-17 Bayer Healthcare Ag Heterocyclic derivatives
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
PT1556342E (pt) 2002-10-28 2008-04-28 Glaxo Group Ltd Derivado de fenetanolamina para o tratamento de doenças respiratórias
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2004161702A (ja) 2002-11-14 2004-06-10 Hokko Chem Ind Co Ltd γ−ジャスモラクトンの製造方法
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10258695A1 (de) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
EP1587818A4 (en) 2003-01-21 2010-10-13 Merck Sharp & Dohme 17-CARBAMOYLOXY CORTISOL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004087142A1 (en) 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
DE602004011513T2 (de) 2003-06-04 2009-01-29 Pfizer Inc. 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US20050133416A1 (en) 2003-12-19 2005-06-23 Bhan Opinder K. Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
RS50538B (sr) 2004-01-22 2010-05-07 Pfizer Limited Sulfonamidni derivati namenjeni lečenju bolesti
ATE375977T1 (de) 2004-01-22 2007-11-15 Pfizer Sulfonamidderivate zur behandlung von krankheiten
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
ES2349470T3 (es) 2004-02-14 2011-01-03 Boehringer Ingelheim International Gmbh Nuevos beta-2-agonistas de acción de larga duración y su utilización como medicamentos.
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
EP1730121B1 (en) 2004-02-26 2013-08-07 Bayer Intellectual Property GmbH 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
HN2004000023A (es) 2004-03-22 2007-11-23 Mars Inc Mascadura para animales
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
CA2560368A1 (en) 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
WO2005092860A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CN1984876A (zh) 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
TW200540154A (en) 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
WO2006016245A1 (en) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006031556A2 (en) 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
EP2118078A2 (en) * 2007-02-07 2009-11-18 Argenta Discovery Ltd New salt

Also Published As

Publication number Publication date
KR20080046179A (ko) 2008-05-26
CN101282949A (zh) 2008-10-08
NZ566069A (en) 2011-03-31
AU2006277768B2 (en) 2012-02-23
RU2008109023A (ru) 2009-09-20
IL189267A0 (en) 2008-08-07
PL1924570T3 (pl) 2011-04-29
JP2009504623A (ja) 2009-02-05
CN101282949B (zh) 2012-05-23
US20100113540A1 (en) 2010-05-06
EP1924570A1 (en) 2008-05-28
US20120277275A1 (en) 2012-11-01
ZA200801603B (en) 2009-08-26
RU2436779C2 (ru) 2011-12-20
PT1924570E (pt) 2010-12-17
NO20081214L (no) 2008-04-23
AU2006277768A1 (en) 2007-02-15
DE602006017715D1 (de) 2010-12-02
WO2007017669A1 (en) 2007-02-15
RS51547B (en) 2011-06-30
UA95255C2 (en) 2011-07-25
ES2352755T3 (es) 2011-02-22
EP2280006A1 (en) 2011-02-02
GB0516313D0 (en) 2005-09-14
CA2617964A1 (en) 2007-02-15
ATE485282T1 (de) 2010-11-15
IL189267A (en) 2013-06-27
EP1924570B1 (en) 2010-10-20
CY1111720T1 (el) 2015-10-07
BRPI0614291A2 (pt) 2011-03-22
HK1117147A1 (en) 2009-01-09
SI1924570T1 (sl) 2011-02-28
DK1924570T3 (da) 2011-01-10
ECSP088253A (es) 2008-04-28
JP5047175B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
HRP20100713T1 (hr) Derivati azola i tiazola i njihova upotreba
KR100659007B1 (ko) 아미드 화합물 및 그 의약으로서의 용도
JP4696069B2 (ja) Ｎ−［ヘテロアリル（ピペリジン−２−イル）メチル］ベンズアミドの誘導体、この調製方法およびこの治療法における使用
RU2008108996A (ru) Производные бицикло[2, 2, 1]гепт-7-иламина и их применения
AU2006228413C1 (en) Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
US7244758B2 (en) N-type calcium channel blockers
CA2624361A1 (en) Methods of using small molecule compounds for neuroprotection
CA2563674A1 (en) .alpha.-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
RS54466B1 (en) NEW COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF Lysosomal Accumulation Disorders
US7507760B2 (en) N-type calcium channel blockers
RU2008125433A (ru) (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
JP2009501775A (ja) 癌治療におけるチアゾール誘導体およびアナログの使用
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
RU2011105813A (ru) Азотсодержащие гетероциклические соединения
NO20054214L (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
RU2009133258A (ru) Гетероциклические производные в качестве ингибиторов мускариновых рецепторов типа мз
EP2155183A1 (en) Amino acid derivatives as calcium channel blockers
US11168071B2 (en) Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
JP2007531755A (ja) 非イミダゾール系複素環式化合物
CA2603683A1 (en) Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands
JP2007501270A5 (hr)
JPWO2020081257A5 (hr)
JP6979968B2 (ja) 環縮合チアゾリノ２−ピリドン類、その製造方法並びに結核の処置及び／又は予防におけるそれらの使用